Mark Wallace, MD
Pain Medicine · San Diego, CANPI 1427098102
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $153,451 of the $220,973 with a category attached, or 69.4%. 23 manufacturers reported payments, led by Boston Scientific at 28.0% of the total. Reporting peaked in 2019 at $68,429 and has fallen 80.9% since, to $13,068 in 2025. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $1194.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$62K
- Pfizer$56K
- Merck$23K
- Tersera Therapeutics LLC$19K
- Daiichi Sankyo Inc.$10K
- Tonix Medicines, Inc.$9K
- plus $42K from 17 others
Across 28 payments — averaging $4237.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Averitas Pharma Inc.$76K
- Vertex$40K
- Endo Pharmaceuticals Inc.$1K
- Purdue Pharma L.p.$1K
What the payments were for
- Consulting fees$153,45169%
- Speaking & faculty fees$50,16123%
- Travel & lodging$12,7786%
- Food & beverage$4,5822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 43 | $61,922 |
| Pfizer | 9 | $56,496 |
| Merck | 29 | $23,461 |
| Tersera Therapeutics LLC | 37 | $18,702 |
| Daiichi Sankyo Inc. | 9 | $9,918 |
| Tonix Medicines, Inc. | 5 | $8,687 |
| GRT US Holding, Inc. | 10 | $8,521 |
| Eli Lilly | 7 | $6,563 |
| Averitas Pharma Inc. | 5 | $5,418 |
| Lexicon Pharmaceuticals, Inc. | 4 | $5,117 |
| Collegium Pharmaceutical, Inc. | 1 | $4,000 |
| SK Life Science, Inc. | 1 | $3,200 |
| GW Research Limited | 1 | $2,800 |
| Masimo Corporation | 2 | $2,375 |
| Orion Corporation | 1 | $1,750 |
| Kowa Pharmaceuticals America, Inc. | 1 | $1,000 |
| Abbott | 7 | $490 |
| Nevro Corp. | 4 | $253 |
| Medtronic | 5 | $187 |
| Relievant Medsystems, Inc. | 1 | $40 |
| Avanos Medical | 1 | $33 |
| Nalu Medical, Inc. | 1 | $22 |
| AbbVie | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRECISION$37,518
- PRIALT$18,425
- CLINICAL TRIAL PRODUCT$17,300
- Qutenza$6,265
- XTAMPZA$4,000
- BELBUCA$4,000
- Nucynta$4,000
- Cenobamate$3,200
- SPECTRA WAVEWRITER$2,810
- WaveWriter Alpha Prime 16$2,020
- GENERAL PAIN MANAGEMENT$1,148
- Seglentis$1,000
- Senza Spinal Cord Stimulation System$124
How this compares
$220,973 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 11 | $15,637 |
| Xtampza ErOxycodone Myristate | 11 | $7,640 |
| Morphine Sulfate ErMorphine Sulfate | 19 | $2,516 |
| Duloxetine Hcl | 40 | $870 |
| Gabapentin | 25 | $821 |
| Morphine Sulfate | 15 | $694 |
| Baclofen | 11 | $634 |
| Oxycodone Hcl | 32 | $537 |
| Hydromorphone Hcl | 17 | $524 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $521 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $261 |
| Tramadol Hcl | 18 | $229 |
| Tizanidine Hcl | 21 | $162 |
| Carisoprodol | 12 | $47 |
| Diazepam | 13 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $4,000 | $7,64011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 pain medicine providers in California.
Other pain medicine in San Diego
- Nathaniel SchusterSan Diego$337K
- Gemayel LeeSan Diego$131K
- Jessica OswaldSan Diego$90K
- Zachary CohenSan Diego$36K
- Joel CastellanosSan Diego$30K
- David HillerSan Diego$30K
- Seth KatzenSan Diego$29K
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.